Search

Author/Creator Dambkowski, Carl L.

1. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results. Issue 11 (24th March 2020)

Authors:
Pal, Sumanta K.; Bajorin, Dean; Dizman, Nazli; Hoffman‐Censits, Jean; Quinn, David I.; Petrylak, Daniel P.; Galsky, Matthew D.; Vaishampayan, Ulka; De Giorgi, Ugo; Gupta, Sumati; Burris, Howard A.; Soifer, Harris S.; Li, Gary; Wang, Hao; Dambkowski, Carl L.; Moran, Susan; Daneshmand, Siamak; Rose...
Journal:
Cancer
Issue:
Volume 126:Issue 11(2020)
Page Start:
2597
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia. (22nd July 2022)

Authors:
Hartley, Iris R.; Roszko, Kelly L.; Li, Xiaobai; Pozo, Karen; Streit, Jamie; del Rivero, Jaydira; Magone, M. Teresa; Smith, Michaele R.; Vold, Roo; Dambkowski, Carl L.; Collins, Michael T.; Gafni, Rachel I.
Journal:
JBMR plus
Issue:
Volume 6:Number 8(2022)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search